Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1;107(6):1470-1473.
doi: 10.3324/haematol.2021.280325.

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study

Idanna Innocenti  1 , Gianluigi Reda  2 , Andrea Visentin  3 , Marta Coscia  4 , Marina Motta  5 , Roberta Murru  6 , Riccardo Moia  7 , Massimo Gentile  8 , Elsa Pennese  9 , Francesca Maria Quaglia  10 , Francesco Albano  11 , Ramona Cassin  2 , Marina Deodato  12 , Claudia Ielo  13 , Anna Maria Frustaci  12 , Alfonso Piciocchi  14 , Arianna Rughini  14 , Valentina Arena  14 , Daniela Di Sevo  14 , Annamaria Tomasso  15 , Francesco Autore  1 , Giovanni Del Poeta  16 , Lydia Scarfò  17 , Francesca Romana Mauro  13 , Alessandra Tedeschi  12 , Livio Trentin  3 , Maurizio Pompili  18 , Robin Foà  13 , Paolo Ghia  17 , Antonio Cuneo  19 , Luca Laurenti  20
Affiliations

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study

Idanna Innocenti et al. Haematologica. .
No abstract available

PubMed Disclaimer

References

    1. Perrillo RP, Gisg R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-244. - PubMed
    1. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215-219. - PubMed
    1. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61(2):703-711. - PMC - PubMed
    1. Hammond SP, Chen K, Pandit A, Davids MS, Issa NC, Marty FM. Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018;131(17):1987-1989. - PubMed
    1. İskender G, İskender D, Ertek M. Hepatitis B Virus Reactivation under ibrutinib treatment in a patient with chronic lymphocytic leukemia. Turk J Haematol. 2020;37(3):208-209. - PMC - PubMed

MeSH terms